A network meta-analysis of randomized controlled trials of biologics for rheumatoid arthritis: a Cochrane overview
Jasvinder A. Singh1,2,3,4,5,6,7, Robin Christensen1,2,3,4,5,6,7, George A. Wells1,2,3,4,5,6,7, María E. Suarez‐Almazor1,2,3,4,5,6,7, Rachelle Buchbinder1,2,3,4,5,6,7, María A. López-Olivo1,2,3,4,5,6,7, Elizabeth Tanjong Ghogomu1,2,3,4,5,6,7, Peter Tugwell1,2,3,4,5,6,7
1Centre for Global Health (Ghogomu, Tugwell), Institute of Popula-tion Health, University of Ottawa, Ottawa, Ont.
2Division of Rheumatology, Rm. 111R, Minneapolis VA Medical Center, 1 Veteran's Dr., Minneapolis MN 55417, USA;
3Frederiksberg Hospital, Frederiksberg, Denmark; the Cardio-vascular Research Reference Centre (Wells),
4From the Department of Medicine (Singh), Minneapolis VA Medical Center and University of Minnesota, Minneapolis and Mayo Clinic College of Medi-cine, Rochester, USA; the Parker Institute: Musculoskeletal Statistics Unit (Christensen),
5Monash University, Malvern, Australia;
6University of Ottawa Heart Insti-tute, Ottawa, Ont.; General Internal Medicine (Suarez-Almazor, Lopez-Olivo), Ambulatory Treatment and Emergency Care,
7University of Texas, M.D. Anderson Cancer Center, Houston, USA; the Monash Department of Clinical Epidemiology at Cabrini Hospital (Buchbinder), Department of Epi-demiology and Preventive Medicine,